ClinicalTrials.gg
CompletedNCT02829320Updated Dec 3, 2019Results posted

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

A Phase 3 interventional study of GSK1278863 and Iron in Anaemia, sponsored by GlaxoSmithKline. Completed at 17 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
22nd of 30
28 · median 76
Started
2016
with 4 others
Phase 3
9 of 30
1 open now
Registered
15th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 22nd largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 15th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This 24-week, Phase 3, open-label, non-comparative, multicentre study aims to evaluate the efficacy and safety of GSK1278863 in Japanese hemodialysis (HD) patients with renal anemia not using erythropoiesis-stimulating agents (ESAs). The primary objective is to evaluate the initial response to GSK1278863 measured by hemoglobin (Hgb) levels in HD patients not using ESAs enrolled in this study. The study is designed to evaluate the appropriateness of the starting dose of GSK1278863 and of the GSK1278863 dose adjustment regimen to achieve or maintain the target Hgb levels. This study will consist of a 4-week screening period, a 24-week treatment period (4-week fixed-dose period and a 20-week dose adjustment period), and a 2- to 4-week follow-up period.

03

Conditions studied

  • Anaemia

Browse trials for

Keywords

  • efficacy
  • hemodialysis (HD)
  • hemoglobin (Hgb)
  • erythropoiesis-stimulating agents (ESAs)
  • GSK1278863
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age (at the time of ): >=20 years
  • Dialysis: Patients on hemodialysis (HD) or hemodiafiltration (HDF)
  • Use of any erythropoiesis stimulating agent (ESA): Newly started dialysis (Dialysis newly started \<12 weeks before screening): Patients not using ESAs after the start of dialysis; Maintenance dialysis (Dialysis started >=12 weeks before screening): Patients not using ESAs within 8 weeks before screening (including interruption of ESA therapy)
  • (Hgb): >=8.0 to \<10.0 g/dL (measured using a point-of-care Hgb measurement device at the study site on Day 1)
  • Iron parameter: Ferritin >100 nanograms (ng)/milliliter (mL) or transferrin saturation (TSAT) >20% (at screening only)
  • Gender (at screening only): Female or male.

A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotropin [hCG] test for females of [FRP] only), not breastfeeding, and at least one of the following conditions applies:

  • Females of non-reproductive potential defined as: Pre-menopausal with one of the following and no plans to utilise assisted reproductive techniques (example [e.g.], in vitro fertilisation or donor embryo transfer): documented bilateral tubal ligation or salpingectomy; documented hysteroscopic tube occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; documented bilateral oophorectomy
  • defined as females 60 years of age or older or In females \<60 years of age, 12 months of spontaneous amenorrhea (In questionable cases, a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause is confirmatory [the reference values are provided separately]). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment.

Females of reproductive potential who agree to follow one of the options listed in the "GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential" from 28 days before the first dose of study treatment until completion of the follow-up visit.

  • Informed consent: Subjects who can provide written informed consent to the study, involving compliance with the requirements and patient responsibilities stated in the consent form and the protocol.

Exclusion criteria

Exclusion Criteria:

CKD related criteria

  • Kidney transplant: Planned living kidney transplant during the study period Anemia-related criteria
  • Aplasia: History of bone marrow aplasia or pure red cell aplasia
  • Other causes of anemia: Pernicious anemia, thalassaemia, sickle cell disease, or myelodysplastic syndrome
  • Gastrointestinal bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or gastrointestinal bleeding within 8 weeks before screening or during a period from screening to Day 1.

Cardiovascular disease-related criteria

  • History of myocardial infarction, acute coronary syndrome, stroke or : Diagnosed within 8 weeks before screening or during a period from screening to Day 1.
  • Heart failure: Class IV heart failure, as defined by the (NYHA) functional classification system
  • interval (QTc) (at screening only): QTc >500 milliseconds (msec), or QTc >530 msec in subject with bundle branch block. Note: Corrected QT interval using Bazett's formula (QTcB) (machine-read or manually) will be used.

Other disease-related criteria

  • Liver disease (if any of the following occurs):

    • (ALT) >2x (ULN)
    • >1.5xULN (If bilirubin fractions are measured and direct bilirubin is \<35%, isolated bilirubin >1.5xULN will be acceptable.)
    • Current unstable active liver or biliary disease (generally defined by the onset of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, persistent jaundice, or cirrhosis). Note: The only exception is squamous cell or basal cell carcinoma of the skin that has been definitively treated >=8 weeks before screening.
  • : History of malignancy within the two years prior to screening, known complex kidney cyst >3 centimeters (cm) (II F, III or IV based on the Bosniak classification) or currently receiving treatment for cancer. Note: The only exception is squamous cell or basal cell carcinoma of the skin that has been definitively treated >=8 weeks before screening.

Concomitant medications and other study treatment-related criteria

  • Iron medication: Planned use of any intravenous iron during the screening period or from Day 1 to Week 4.

Note:

  • Patients on oral iron may be enrolled if the iron dose regimen is unchanged during the screening period and from Day 1 to Week 4.
  • Patients on anti-hyperphosphatemia medication containing iron (e.g., ferric citrate hydrate) for at least 12 weeks before screening may be enrolled if the medication is continued during the screening and from Day 1 to Week 4.

    • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to any in the product
    • Drugs and dietary supplements: Current use of prohibited prescription drugs, non-prescription drugs, or dietary supplements or planned use of any of these drugs during the study period (prohibited drugs: strong cytochrome P450 (CYP)2C8 inducers and inhibitors)
    • Exposure to any other investigational product: Use of an investigational product within the past 30 days or five half lives of that investigational product (whichever is longer).
    • Prior treatment with GSK1278863: Prior treatment with GSK1278863 for >30 days General health-related criteria
    • Other conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance or prevent understanding of the aims or investigational procedures or possible consequences of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    GSK1278863

    Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.

    Drug: GSK1278863 · Drug: Iron

Interventions

  • GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.

  • DrugIron

    Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hgb at Week 4

    Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The analysis was performed on All Treated Subjects Population which comprised of all participants who received at least one dose of GSK1278863.

    Time frame: Baseline and Week 4

  2. Number of Participants by Hgb Change From Baseline Category at Week 4

    Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The change in Hgb at Week 4 was classified into different categories (i.e., \<=-2.0, \>-2.0 to -1.0, \>-1.0 to 0, \>0 to 1.0, \>1.0 to 2.0, and \>2 g/dL), and the number of participants in each category were summarized.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Hgb Values at the Indicated Time Points

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer.

    Time frame: Up to Week 24

  2. Change From Baseline in Hgb at the Indicated Time Points

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The Baseline value was the latest pre-dose assessment. Change from Baseline at indicated time-points was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to Week 24

  3. Number of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL)

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants with Hgb withinthe target range (10.0 to 12.0 g/dL) at each assessment visit was summarized.

    Time frame: Up to Week 24

  4. Time to Reach the Lower Target Hgb Level (10.0 g/dL)

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. Participants who could not reach lower target were regarded as censored. The time (in days) to reach the lower target Hgb level (10.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method.

    Time frame: Up to Week 24

  5. Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of less than 7.5 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

    Time frame: Up to Week 24

  6. Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb increase of more than 2.0 g/dL over any 4 weeks were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

    Time frame: Up to Week 24

  7. Number of Participants Who Had Hgb Level of More Than 13.0 g/dL

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

    Time frame: Up to Week 24

  8. Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL

    Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of episodes in participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

    Time frame: Up to Week 24

  9. Area Under the Concentration-time Curve (AUC) From Time Zero to 4 Hours (AUC [0-4]) of GSK1278863

    Blood samples were collected to evaluate AUC (0-4) at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Population consisted of all participants who received GSK1278863 with the PK samples collected and analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.

    Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24

  10. Maximum Observed Concentration (Cmax) of GSK1278863

    Blood samples were collected to evaluate Cmax at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.

    Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24

  11. Monthly Average Dose of Intravenous (IV) Iron During the Treatment Period

    Records of on-therapy iron medication were used to calculate average quarterly IV iron dose. Quarter 1 = (Randomization Date - Treatment Start Date at Week 12 - 1 \[day\]). Quarter 2 = (Treatment Start Date at Week 12 - Study Treatment Stop Date). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 24

  12. Number of Participants Who Used Iron During the Treatment Period

    The number of participants who used iron (both IV and oral iron) during the treatment period were summarized.

    Time frame: Up to Week 24

  13. Change From Baseline in Ferritin

    Blood samples were collected from participants for measurement of serum ferritin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to Week 24

  14. Percent Change From Baseline in TSAT

    Blood samples were collected from participants for measurement of TSAT at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1).

    Time frame: Baseline and up to Week 24

  15. Percent Change From Baseline in Hepcidin

    Blood samples were collected from participants for measurement of hepcidin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). If a laboratory value had a non-detectable level reported in the database, where the numeric value was missing, the value was not included in a summary. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Baseline and up to Week 24

  16. Change From Baseline in Serum Iron

    Blood samples were collected from participants for measurement of serum iron at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to Week 24

  17. Change From Baseline in Total Iron Binding Capacity (TIBC)

    Blood samples were collected from participants for measurement of TIBC at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to Week 24

  18. Dose Level of GSK1278863 at Indicated Time Points

    Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. Mean dose during Week 12 to 24 is the average of dose at Weeks 12, 16, and 20.

    Time frame: Up to Week 24

  19. Number of Participants With Frequency of Dose Adjustments

    Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. For dose adjustments frequency, the number of participants were provided by the number of dose adjustments (i.e. zero, one, two, three, four, and five or more).

    Time frame: Up to Week 24

  20. Duration of Treatment Interruption Due to Hgb >13 g/dL

    Hgb values were used for making decision of treatment interruption. On-therapy Hgb values observed in both scheduled and unscheduled visits were counted. Participants who have no treatment interruption due to Hgb \>13.0 g/dL are not included

    Time frame: Up to Week 24

07

Results

Posted Jul 13, 2018

Participant flow

This was a 24-week, Phase 3, open-label, non-comparative, multicenter study to evaluate the efficacy and safety of GSK1278863 in Japanese hemodialysis participants with renal anemia not using Erythropoiesis Stimulating Agents. The study was conducted at 18 centers in Japan from 08-Aug-2016 to 17-Oct-2017.

Participant flow — Overall Study
MilestoneAll Participants
Started28
Completed28
Not completed0

Outcome measures

PrimaryChange From Baseline in Hgb at Week 4

Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The analysis was performed on All Treated Subjects Population which comprised of all participants who received at least one dose of GSK1278863.

Time frame:
Baseline and Week 4
Reported as:
Mean · G/dL
Change From Baseline in Hgb at Week 4
G/dLAll Participants
Change From Baseline in Hgb at Week 40.79 (0.53 to 1.05)
PrimaryNumber of Participants by Hgb Change From Baseline Category at Week 4

Blood samples were collected from participants for measurement of Hgb values. The Baseline value was the latest pre-dose assessment. Change from Baseline at Week 4 was calculated by subtracting Baseline value from the post-dose visit value. The change in Hgb at Week 4 was classified into different categories (i.e., \<=-2.0, \>-2.0 to -1.0, \>-1.0 to 0, \>0 to 1.0, \>1.0 to 2.0, and \>2 g/dL), and the number of participants in each category were summarized.

Time frame:
Baseline and Week 4
Reported as:
Count of participants · Participants
Number of Participants by Hgb Change From Baseline Category at Week 4
ParticipantsAll Participants
<= -2.00
> -2.0 to -1.00
> -1.0 to 04
> 0 to 1.013
> 1.0 to 2.011
> 2.00
SecondaryHgb Values at the Indicated Time Points

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer.

Time frame:
Up to Week 24
Reported as:
Mean · G/dL
Hgb Values at the Indicated Time Points
G/dLAll Participants
Day 19.10 ± 0.696
Week 49.90 ± 0.907
Week 810.76 ± 0.957
Week 1211.09 ± 1.117
Week 1611.38 ± 1.286
Week 2011.34 ± 1.169
Week 2411.12 ± 1.210
SecondaryChange From Baseline in Hgb at the Indicated Time Points

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The Baseline value was the latest pre-dose assessment. Change from Baseline at indicated time-points was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to Week 24
Reported as:
Mean · G/dL
Change From Baseline in Hgb at the Indicated Time Points
G/dLAll Participants
Week 40.79 ± 0.673
Week 81.66 ± 0.773
Week 121.98 ± 0.984
Week 162.28 ± 1.248
Week 202.24 ± 1.174
Week 242.01 ± 1.121
SecondaryNumber of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL)

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants with Hgb withinthe target range (10.0 to 12.0 g/dL) at each assessment visit was summarized.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Had Hgb Level Within the Target Range (10.0-12.0 g/dL)
ParticipantsAll Participants
Day 1, within range3
Week 4, within range13
Week 8, within range20
Week 12, within range18
Week 16, within range17
Week 20, within range20
Week 24, within range23
SecondaryTime to Reach the Lower Target Hgb Level (10.0 g/dL)

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. Participants who could not reach lower target were regarded as censored. The time (in days) to reach the lower target Hgb level (10.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method.

Time frame:
Up to Week 24
Reported as:
Median · Days
Time to Reach the Lower Target Hgb Level (10.0 g/dL)
DaysAll Participants
Time to Reach the Lower Target Hgb Level (10.0 g/dL)57.0 (29.0 to 57.0)
SecondaryNumber of Participants Who Had Hgb Level of Less Than 7.5 g/dL

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of less than 7.5 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL
ParticipantsAll Participants
Number of Participants Who Had Hgb Level of Less Than 7.5 g/dL0
SecondaryNumber of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb increase of more than 2.0 g/dL over any 4 weeks were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
ParticipantsAll Participants
Number of Participants Who Had Hgb Increase of More Than 2 g/dL Over Any 4 Weeks1
SecondaryNumber of Participants Who Had Hgb Level of More Than 13.0 g/dL

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Had Hgb Level of More Than 13.0 g/dL
ParticipantsAll Participants
Number of Participants Who Had Hgb Level of More Than 13.0 g/dL3
SecondaryNumber of Episodes of Achieving Hgb Level of More Than 13.0 g/dL

Blood samples were collected from participants for measurement of Hgb values at indicated time points. Hgb was evaluated using Hgb analyzer. The number of episodes in participants who had Hgb level of more than 13.0 g/dL were summarized. On-therapy Hgb values observed in both scheduled and unscheduled visits were included.

Time frame:
Up to Week 24
Reported as:
Number · Episodes
Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL
EpisodesAll Participants
Number of Episodes of Achieving Hgb Level of More Than 13.0 g/dL7
SecondaryArea Under the Concentration-time Curve (AUC) From Time Zero to 4 Hours (AUC [0-4]) of GSK1278863

Blood samples were collected to evaluate AUC (0-4) at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Population consisted of all participants who received GSK1278863 with the PK samples collected and analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.

Time frame:
1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Reported as:
Geometric mean · Hour*nanogram per milliliter (h*ng/mL)
Area Under the Concentration-time Curve (AUC) From Time Zero to 4 Hours (AUC [0-4]) of GSK1278863
Hour*nanogram per milliliter (h*ng/mL)GSK1278863 1 mgGSK1278863 2 mgGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 12 mgGSK1278863 18 mg
AUC (0-4), Week 12, n=0,4,14,8,1,0,0—25.7228 ± 289.995.1319 ± 111.9200.6036 ± 62.9233.3933 ± NA——
AUC (0-4), Week 24, n=1,8,8,5,2,1,143.3100 ± NA33.8941 ± 230.986.3702 ± 58.9133.3020 ± 50.9437.0983 ± 18.7749.4583 ± NA126.2883 ± NA
AUC (0-4), All, n=1,12,22,13,3,1,143.3100 ± NA30.9164 ± 225.391.8474 ± 91.1171.4229 ± 60.8354.6083 ± 40.0749.4583 ± NA126.2883 ± NA
SecondaryMaximum Observed Concentration (Cmax) of GSK1278863

Blood samples were collected to evaluate Cmax at 1, 2, 3 and 4 hours post dose at Weeks 12 and 24. PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indiates data was not available. Geometric coefficient of variation could not be calculated when number of participant was equal to 1.

Time frame:
1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of GSK1278863
ng/mLGSK1278863 1 mgGSK1278863 2 mgGSK1278863 4 mgGSK1278863 6 mgGSK1278863 8 mgGSK1278863 12 mgGSK1278863 18 mg
Cmax, Week 12, n=0,4,14,8,1,0,0—13.9578 ± 340.657.6572 ± 81.2122.9883 ± 56.9179.0000 ± NA——
Cmax, Week 24, n=1,8,8,5,2,1,127.5000 ± NA18.3448 ± 202.344.8853 ± 49.8100.2261 ± 41.3202.9384 ± 3.5311.0000 ± NA93.4000 ± NA
Cmax, All, n=1,12,22,13,3,1,127.5000 ± NA16.7474 ± 217.452.6391 ± 70.4113.6784 ± 50.4194.6229 ± 7.7311.0000 ± NA93.4000 ± NA
SecondaryMonthly Average Dose of Intravenous (IV) Iron During the Treatment Period

Records of on-therapy iron medication were used to calculate average quarterly IV iron dose. Quarter 1 = (Randomization Date - Treatment Start Date at Week 12 - 1 \[day\]). Quarter 2 = (Treatment Start Date at Week 12 - Study Treatment Stop Date). Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 24
Reported as:
Mean · Mg
Monthly Average Dose of Intravenous (IV) Iron During the Treatment Period
MgAll Participants
Quarter 1; n= 3231.61 ± 99.916
Quarter 2; n= 4217.19 ± 86.529
SecondaryNumber of Participants Who Used Iron During the Treatment Period

The number of participants who used iron (both IV and oral iron) during the treatment period were summarized.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Used Iron During the Treatment Period
ParticipantsAll Participants
Oral iron9
Intravenous iron4
Any iron medication12
SecondaryChange From Baseline in Ferritin

Blood samples were collected from participants for measurement of serum ferritin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to Week 24
Reported as:
Mean · Microgram per liter (µg/L)
Change From Baseline in Ferritin
Microgram per liter (µg/L)All Participants
Week 4-80.11 ± 51.826
Week 12-126.29 ± 120.382
Week 24-107.03 ± 143.048
SecondaryPercent Change From Baseline in TSAT

Blood samples were collected from participants for measurement of TSAT at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1).

Time frame:
Baseline and up to Week 24
Reported as:
Geometric mean · Percentage of transferrin
Percent Change From Baseline in TSAT
Percentage of transferrinAll Participants
Week 4-23.06 (-32.43 to -12.38)
Week 12-15.31 (-33.79 to 8.32)
Week 24-10.07 (-25.49 to 8.55)
SecondaryPercent Change From Baseline in Hepcidin

Blood samples were collected from participants for measurement of hepcidin at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). If a laboratory value had a non-detectable level reported in the database, where the numeric value was missing, the value was not included in a summary. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Baseline and up to Week 24
Reported as:
Geometric mean · Percentage of hepcidin
Percent Change From Baseline in Hepcidin
Percentage of hepcidinAll Participants
Week 4, n=26-64.78 (-71.34 to -56.71)
Week 12, n=22-61.74 (-74.51 to -42.57)
Week 24, n=21-55.67 (-72.52 to -28.47)
SecondaryChange From Baseline in Serum Iron

Blood samples were collected from participants for measurement of serum iron at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to Week 24
Reported as:
Mean · Micromoles per liter (µmol/L)
Change From Baseline in Serum Iron
Micromoles per liter (µmol/L)All Participants
Week 4-0.8123 ± 4.92624
Week 122.0916 ± 10.74722
Week 241.4584 ± 7.72121
SecondaryChange From Baseline in Total Iron Binding Capacity (TIBC)

Blood samples were collected from participants for measurement of TIBC at indicated time points. The Baseline value was the latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to Week 24
Reported as:
Mean · umol/L
Change From Baseline in Total Iron Binding Capacity (TIBC)
umol/LAll Participants
Week 48.5904 ± 4.93732
Week 1210.8611 ± 6.32355
Week 249.3388 ± 9.92131
SecondaryDose Level of GSK1278863 at Indicated Time Points

Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. Mean dose during Week 12 to 24 is the average of dose at Weeks 12, 16, and 20.

Time frame:
Up to Week 24
Reported as:
Median · mg
Dose Level of GSK1278863 at Indicated Time Points
mgAll Participants
Day 14.0 (4 to 4)
Week 44.0 (2 to 6)
Week 84.0 (2 to 8)
Week 124.0 (0 to 8)
Week 164.0 (0 to 12)
Week 204.0 (0 to 18)
Week 12 to 244.00 (0.0 to 12.7)
SecondaryNumber of Participants With Frequency of Dose Adjustments

Dose adjustment algorithm was used which was based on Hgb values at scheduled visits. Hgb values measured at unscheduled visits were not included. For dose adjustments frequency, the number of participants were provided by the number of dose adjustments (i.e. zero, one, two, three, four, and five or more).

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Frequency of Dose Adjustments
ParticipantsAll Participants
Any dose adjustments21
Number of dose adjustments=07
Number of dose adjustments=19
Number of dose adjustments=27
Number of dose adjustments=34
Number of dose adjustments=41
Number of dose adjustments=5 or more0
SecondaryDuration of Treatment Interruption Due to Hgb >13 g/dL

Hgb values were used for making decision of treatment interruption. On-therapy Hgb values observed in both scheduled and unscheduled visits were counted. Participants who have no treatment interruption due to Hgb \>13.0 g/dL are not included

Time frame:
Up to Week 24
Reported as:
Median · Days
Duration of Treatment Interruption Due to Hgb >13 g/dL
DaysAll Participants
Duration of Treatment Interruption Due to Hgb >13 g/dL84 (28 to 84)

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of study treatment (Day 1) until Week 24.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/28 (0%)3/28 (10.7%)12/28 (42.9%)
Most frequent serious events
Most frequent serious events
EventAll Participants
Shunt occlusionInjury, poisoning and procedural complications2/28
Device dislocationProduct Issues1/28
Most frequent other events
Most frequent other events
EventAll Participants
NasopharyngitisInfections and infestations9/28
Infected dermal cystInfections and infestations2/28
Shunt stenosisInjury, poisoning and procedural complications2/28

Baseline characteristics

All Treated Subjects

Age, Continuous
Age, Continuous(Years)All Participants
Mean62.5 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female3
Male25
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of Participants)All Participants
Asian - Japanese Heritage28
Dialysis Status
Dialysis Status(Participants)All Participants
Newly started dialysis11
Maintenance dialysis17
08

Study locations

17 sites
  • GSK Investigational Site
    Aichi, 455-8530, Japan
  • GSK Investigational Site
    Aichi, 457-8511, Japan
  • GSK Investigational Site
    Fukuoka, 802-8555, Japan
  • GSK Investigational Site
    Hokkaido, 065-8611, Japan
  • GSK Investigational Site
    Ibaraki, 300-0028, Japan
  • GSK Investigational Site
    Ibaraki, 302-0022, Japan
  • GSK Investigational Site
    Ibaraki, 306-0433, Japan
  • GSK Investigational Site
    Kagoshima, 891-0105, Japan
  • GSK Investigational Site
    Kumamoto, 861-8520, Japan
  • GSK Investigational Site
    Kyoto, 613-0034, Japan
  • GSK Investigational Site
    Mie, 510-8101, Japan
  • GSK Investigational Site
    Nagano, 392-8510, Japan
  • GSK Investigational Site
    Nagano, 399-8292, Japan
  • GSK Investigational Site
    Oita, 870-0844, Japan
  • GSK Investigational Site
    Osaka, 555-0001, Japan
  • GSK Investigational Site
    Shiga, 523-0082, Japan
  • GSK Investigational Site
    Yamagata, 990-0834, Japan
09

References and documents

Publications

  • Tsubakihara Y, Akizawa T, Nangaku M, Onoue T, Yonekawa T, Matsushita H, Endo Y, Cobitz A. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. Ther Apher Dial. 2020 Apr;24(2):108-114. doi: 10.1111/1744-9987.12962. Epub 2019 Aug 13. PubMed 31306555 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in May 2017, 9 months.

Results were first posted in Jul 2018, 1 year 1 month after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 9 months is below that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2016
First posted
Jul 12, 2016
StartActual
Aug 8, 2016
Primary completionActual
May 16, 2017
CompletionActual
Oct 17, 2017
Results first posted
Jul 13, 2018
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02829320
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 12, 2016
Start date
Aug 8, 2016
Primary completion
May 16, 2017
Completion
Oct 17, 2017
Results posted
Jul 13, 2018
Last update
Dec 3, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion